Generic Products July 2020

Pharmacy TimesJuly 2020
Volume 88
Issue 7

Generic products for July 2020.


Marketed by: American Regent

Compare to: Cardene

American Regent is introducing a generic nicardipine hydrochloride injection, a calcium channel blocker indicated for the short-term treatment of hypertension when oral therapy is not feasible. The Centers for Disease Control Prevention (CDC) has said that high blood pressure affects tens of millions of adults in the United States, making available treatments especially necessary. This product is intended to offer another option for the treatment of hypertension, particularly because the drug is prone to shortages, according to a statement from American Regent.

For more information:


Marketed by: Fresenius Kabi

Compare to: Fresenius Kabi's micafungin for injection

The first generic of Astellas Pharma’s Mycamine, offers new options for adult and pediatric patients with candidemia or esophageal candidiasis, and for prophylaxis of candida infections. The drug is available in 50- and 100-mg strengths, and in 10-ml vials. Invasive candidemia is one of the most common bloodstream infections in the

United States, affecting an estimated 9 per 100,000 people between 2013 and 2017 according to the CDC.

For more information:


Marketed by: Zydus Cadila

Compare to: Exjade Tablets

The FDA recently approved Zydus Cadila’s generic deferasirox tablets for oral suspension, available in doses of 125, 250, and 500 mg. Deferasirox functions by binding to iron and removing it from the bloodstream and is used to treat iron overload caused by blood transfusions in adults and children at least 2 years old. It can also be used to treat chronic iron overload syndrome caused by non—transfusion dependent thalassemia in adults and children at least 10 years old.

For more information:


Marketed by: Hikma

Compare to: Buprenex

Hikma is releasing a generic buprenorphine hydrochloride injection, indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Providers should be aware of several warnings, including for abuse and addiction, life-threatening respiratory depression, neonatal opioid withdrawal syndrome, and others.

For more information:

Recent Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs